25328

533573

APLLTD

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

ALEMBIC PHARMA LTD Share Price Today

ALEMBIC PHARMA LTD is currently trading at ₹743.35, up by ₹8.69 from the previous close. The stock touched an intraday high of ₹754.45 and a low of ₹738.30 during the latest trading session. Over the past one year, ALEMBIC PHARMA LTD has delivered a loss of 26.26%, while the stock has declined 6.91% in the last one month.

ALEMBIC PHARMA LTD performance

Today’s low Today’s high
₹ 738.30 ₹ 754.45
₹ 743.35
52 week low 52 week high
₹ 635.80 ₹ 1107.90
₹ 743.35
Open Price ₹ 749.25
Prev. Close ₹ 734.65
Volume (Shares) 86226.00
Total traded value ₹ 640.96
Upper Circuit ₹ 881.55
Lower Circuit ₹ 587.75
info

Investment Returns

Over 1 Month -6.91% Over 3 Months 4.04% Over 6 Months -16.99% Over 1 Year -26.26%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ALEMBIC PHARMA LTD fundamentals


  • Market cap (Cr) 14,611.50
  • P/E Ratio (TTM) 22.56
  • Beta 0.92
  • Book Value / share 285.67
  • Return on equity 9.96%
  • EPS (TTM) 35.39
  • Dividend yield 1.63%
  • Net profit/quarter (Cr) 243.07
info icon alternate text
  • Market cap (Cr) 14,606.60
  • P/E Ratio (TTM) 22.56
  • Beta 0.88
  • Book Value / share 285.67
  • Return on equity 9.96%
  • EPS (TTM) 35.39
  • Dividend yield 1.63%
  • Net profit/quarter (Cr) 243.07
info icon alternate text

ALEMBIC PHARMA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 1718.74
Operating Expense 1546.40
Net Profit 243.07
Net Profit Margin (%) 14.14
Earnings Per Share (EPS) 12.37
EBITDA 275.19
Effective Tax Rate (%) -40.13
Particulars DEC 2025 (Values in Cr)
Revenue 1642.24
Operating Expense 1471.96
Net Profit 114.47
Net Profit Margin (%) 6.97
Earnings Per Share (EPS) 5.82
EBITDA 240.10
Effective Tax Rate (%) 17.51
Particulars SEP 2025 (Values in Cr)
Revenue 1796.24
Operating Expense 1591.37
Net Profit 179.36
Net Profit Margin (%) 9.98
Earnings Per Share (EPS) 9.12
EBITDA 314.80
Effective Tax Rate (%) 17.09
Particulars JUN 2025 (Values in Cr)
Revenue 1494.17
Operating Expense 1376.44
Net Profit 103.52
Net Profit Margin (%) 6.92
Earnings Per Share (EPS) 5.27
EBITDA 221.53
Effective Tax Rate (%) 17.52
Particulars MAR 2025 (Values in Cr)
Revenue 1570.64
Operating Expense 1492.29
Net Profit 75.34
Net Profit Margin (%) 4.79
Earnings Per Share (EPS) 3.83
EBITDA 183.87
Effective Tax Rate (%) 17.71
Particulars MAR 2026 (Values in Cr)
Revenue 6651.38
Operating Expense 5986.18
Net Profit 640.42
Net Profit Margin (%) 9.62
Earnings Per Share (EPS) 32.58
EBITDA 1051.62
Effective Tax Rate (%) 2.09
Particulars MAR 2025 (Values in Cr)
Revenue 6032.63
Operating Expense 5484.79
Net Profit 503.12
Net Profit Margin (%) 8.33
Earnings Per Share (EPS) 25.60
EBITDA 962.14
Effective Tax Rate (%) 17.33
Particulars MAR 2024 (Values in Cr)
Revenue 5874.06
Operating Expense 5201.15
Net Profit 666.48
Net Profit Margin (%) 11.34
Earnings Per Share (EPS) 33.91
EBITDA 1029.84
Effective Tax Rate (%) 5.36
Particulars MAR 2023 (Values in Cr)
Revenue 5149.00
Operating Expense 4806.62
Net Profit 346.73
Net Profit Margin (%) 6.73
Earnings Per Share (EPS) 17.64
EBITDA 667.88
Effective Tax Rate (%) -0.23
Particulars MAR 2022 (Values in Cr)
Revenue 5035.41
Operating Expense 4428.54
Net Profit 543.55
Net Profit Margin (%) 10.79
Earnings Per Share (EPS) 27.65
EBITDA 959.95
Effective Tax Rate (%) 17.39
Particulars MAR 2025 (Values in Cr)
Book Value / Share 264.10
ROE % 11.63
ROCE % 13.08
Total Debt to Total Equity 0.18
EBITDA Margin 15.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 245.14
ROE % 13.40
ROCE % 12.93
Total Debt to Total Equity 0.13
EBITDA Margin 15.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 222.36
ROE % 7.12
ROCE % 7.20
Total Debt to Total Equity 0.15
EBITDA Margin 12.03
Particulars MAR 2022 (Values in Cr)
Book Value / Share 266.47
ROE % 10.11
ROCE % 10.91
Total Debt to Total Equity 0.13
EBITDA Margin 17.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share 257.80
ROE % 26.91
ROCE % 25.51
Total Debt to Total Equity 0.28
EBITDA Margin 29.07
Particulars MAR 2025 (Values in Cr)
Book Value / Share 264.30
ROE % 9.96
ROCE % 11.40
Total Debt to Total Equity 0.17
EBITDA Margin 15.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 249.75
ROE % 14.30
ROCE % 14.13
Total Debt to Total Equity 0.13
EBITDA Margin 17.53
Particulars MAR 2023 (Values in Cr)
Book Value / Share 224.59
ROE % 7.15
ROCE % 6.98
Total Debt to Total Equity 0.15
EBITDA Margin 12.97
Particulars MAR 2022 (Values in Cr)
Book Value / Share 269.16
ROE % 10.46
ROCE % 11.38
Total Debt to Total Equity 0.12
EBITDA Margin 19.06
Particulars MAR 2021 (Values in Cr)
Book Value / Share 259.57
ROE % 25.96
ROCE % 24.67
Total Debt to Total Equity 0.27
EBITDA Margin 30.26
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 90.10
Total Assets 7772.93
Total Liabilities 7772.93
Total Equity 5189.52
Share Outstanding 19
Price to Book Ratio 3.52
Return on Assets (%) 7.50
Return on Capital (%) 9.14
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 126.57
Total Assets 6445.58
Total Liabilities 6445.58
Total Equity 4818.20
Share Outstanding 19
Price to Book Ratio 3.93
Return on Assets (%) 9.55
Return on Capital (%) 11.73
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 82.27
Total Assets 6182.83
Total Liabilities 6182.83
Total Equity 4370.47
Share Outstanding 19
Price to Book Ratio 2.21
Return on Assets (%) 5.53
Return on Capital (%) 6.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 69.43
Total Assets 7122.03
Total Liabilities 7122.03
Total Equity 5237.54
Share Outstanding 19
Price to Book Ratio 2.75
Return on Assets (%) 7.31
Return on Capital (%) 8.88
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 105.84
Total Assets 6708.98
Total Liabilities 6708.98
Total Equity 5066.97
Share Outstanding 19
Price to Book Ratio 3.72
Return on Assets (%) 17.08
Return on Capital (%) 20.6
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 20.85
Total Assets 7556.27
Total Liabilities 7556.27
Total Equity 5194.74
Share Outstanding 19
Price to Book Ratio 3.52
Return on Assets (%) 6.65
Return on Capital (%) 7.94
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 26.49
Total Assets 6398.55
Total Liabilities 6398.55
Total Equity 4908.91
Share Outstanding 19
Price to Book Ratio 3.93
Return on Assets (%) 10.41
Return on Capital (%) 12.51
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 28.46
Total Assets 6130.42
Total Liabilities 6130.42
Total Equity 4414.29
Share Outstanding 19
Price to Book Ratio 2.21
Return on Assets (%) 5.65
Return on Capital (%) 6.87
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 21.90
Total Assets 7074.04
Total Liabilities 7074.04
Total Equity 5290.34
Share Outstanding 19
Price to Book Ratio 2.75
Return on Assets (%) 7.68
Return on Capital (%) 9.18
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 61.44
Total Assets 6643.47
Total Liabilities 6643.47
Total Equity 5101.81
Share Outstanding 19
Price to Book Ratio 3.72
Return on Assets (%) 16.50
Return on Capital (%) 19.58
Particulars MAR 2025 (Values in Cr)
Net Income 707.18
Cash from Operations 159.35
Cash from Investing -568.41
Cash from Financing 443.73
Net change in Cash -36.73
Free Cash Flow 722.97
Particulars MAR 2024 (Values in Cr)
Net Income 631.83
Cash from Operations 823.05
Cash from Investing -320.61
Cash from Financing -437.86
Net change in Cash 44.73
Free Cash Flow 1150.52
Particulars MAR 2023 (Values in Cr)
Net Income 354.59
Cash from Operations 784.64
Cash from Investing -447.60
Cash from Financing -261.96
Net change in Cash 14.39
Free Cash Flow 1228.05
Particulars MAR 2022 (Values in Cr)
Net Income 625.39
Cash from Operations 675.78
Cash from Investing -371.97
Cash from Financing -217.35
Net change in Cash -36.97
Free Cash Flow 1101.42
Particulars MAR 2021 (Values in Cr)
Net Income 1368.08
Cash from Operations 1708.82
Cash from Investing -838.81
Cash from Financing -597.43
Net change in Cash 27.15
Free Cash Flow 2368.34
Particulars MAR 2025 (Values in Cr)
Net Income 608.59
Cash from Operations 272.22
Cash from Investing -636.06
Cash from Financing 403.61
Net change in Cash -5.90
Free Cash Flow 835.23
Particulars MAR 2024 (Values in Cr)
Net Income 704.23
Cash from Operations 782.80
Cash from Investing -329.02
Cash from Financing -445.29
Net change in Cash -1.54
Free Cash Flow 1107.32
Particulars MAR 2023 (Values in Cr)
Net Income 345.93
Cash from Operations 784.03
Cash from Investing -460.98
Cash from Financing -261.16
Net change in Cash 8.11
Free Cash Flow 1227.29
Particulars MAR 2022 (Values in Cr)
Net Income 658.01
Cash from Operations 674.06
Cash from Investing -368.72
Cash from Financing -216.64
Net change in Cash -40.10
Free Cash Flow 1096.42
Particulars MAR 2021 (Values in Cr)
Net Income 1337.74
Cash from Operations 1628.92
Cash from Investing -835.72
Cash from Financing -533.76
Net change in Cash 19.00
Free Cash Flow 2285.91
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.52 13.02 1.52 241.55 23.12 38.85
BLISS GVS PHARMA LTD. 436.05 35.28 3.86 4612.93 118.35 462.70
CIPLA LTD 1383.00 29.35 3.24 111725.01 1165.55 1672.20
FERMENTA BIOTECH LTD. 328.55 14.49 2.37 966.96 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.52 22.04 4.06 241.55 23.12 38.85
AMRUTAJAN HEALTH LTD 562.65 25.22 4.39 1626.66 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8248.80 107.73 23.62 20622.00 7630.00 10653.05
BLISS GVS PHARMA LTD. 436.05 46.89 3.99 4612.93 118.35 462.70

ALEMBIC PHARMA LTD shareholding pattern

Holding
9.82%
69.73%
4.25%
16.17%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

ALEMBIC PHARMA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
743.35 1.18 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 735.90
  • 26 Days 744.00
  • 10 Days 737.90
  • 50 Days 745.70
  • 12 Days 739.10
  • 100 Days 762.90
  • 20 Days 742.90
  • 200 Days 811.50
741.12 PIVOT
First Support 723.03 First Resistance 752.73 Second Support 711.42 Second Resistance 770.82 Third Support 693.33 Third Resistance 782.43
RSI 46.18 ADX 8.45 MACD -4.89 Williams % R -62.42 Commodity Channel Index (CCI) -27.33
Date 2026-06-11 Week 212086.00 Same Day 123961.00 Month 96332.00
1 Year 0.92 3 Year 0.72
Over 1 Month
-6.91% down
Over 1 Year
-26.26% down
Over 3 Months
4.04% down
Over 3 Years
8.08% down
Over 6 Months
-16.99% down
Over 5 Years
-6.09% down

ALEMBIC PHARMA LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
29 Jul 2025 11.0 Final 29 Jul 2025 Equity shares
15 Jul 2024 11.0 Final 15 Jul 2024 Equity shares
28 Jul 2023 8.0 Final 28 Jul 2023 Equity shares
17 Aug 2022 10.0 Interim 18 Aug 2022 Equity shares
19 Jul 2021 14.0 Final 21 Jul 2021 Equity shares
16 Mar 2020 7.0 Interim 17 Mar 2020 Equity shares
16 Mar 2020 3.0 Special 17 Mar 2020 Equity shares
18 Jul 2019 5.5 Final 22 Jul 2019 Equity shares
18 Jul 2018 4.0 Final 20 Jul 2018 Equity shares
11 Jul 2017 4.0 Final 13 Jul 2017 Equity shares
20 Jul 2016 4.0 Final 22 Jul 2016 Equity shares
22 Jul 2015 3.5 Final 24 Jul 2015 Equity shares
17 Jul 2014 3.0 Final 21 Jul 2014 Equity shares
29 Jul 2013 2.5 Final 31 Jul 2013 Equity shares
31 Jul 2012 1.4 Final 02 Aug 2012 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
29 Jul 2025 11.0 Final 29 Jul 2025 Equity shares
15 Jul 2024 11.0 Final 15 Jul 2024 Equity shares
28 Jul 2023 8.0 Final 28 Jul 2023 Equity shares
17 Aug 2022 10.0 Interim 18 Aug 2022 Equity shares
19 Jul 2021 14.0 Final 21 Jul 2021 Equity shares
16 Mar 2020 7.0 Interim 17 Mar 2020 Equity shares
16 Mar 2020 3.0 Special 17 Mar 2020 Equity shares
18 Jul 2019 5.5 Final 22 Jul 2019 Equity shares
18 Jul 2018 4.0 Final 20 Jul 2018 Equity shares
11 Jul 2017 4.0 Final 13 Jul 2017 Equity shares
20 Jul 2016 4.0 Final 22 Jul 2016 Equity shares
22 Jul 2015 3.5 Final 24 Jul 2015 Equity shares
17 Jul 2014 3.0 Final 21 Jul 2014 Equity shares
29 Jul 2013 2.5 Final 31 Jul 2013 Equity shares
31 Jul 2012 1.4 Final 02 Aug 2012 Equity shares

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Alembic Pharmaceuticals Ltd?

Answer Field

Alembic Pharmaceuticals Ltd share price is for NSE ₹ 743.35 & for BSE ₹ 739.95 as on Jun 12 2026 03:30 PM.

What is the Market Cap of Alembic Pharmaceuticals Ltd Share?

Answer Field

The market cap of Alembic Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 12 2026 03:30 PM.

What is the 52 Week High and Low of Alembic Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Alembic Pharmaceuticals Ltd for NSE is ₹ 1,107.90 and ₹ 635.80 and for BSE is ₹ 1,107.80 and ₹ 635.30.

What is 1 year return for Alembic Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been -26.26%.

What is the P/E Ratio of Alembic Pharmaceuticals Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM the price-to-earnings (PE) ratio for Alembic Pharmaceuticals Ltd share is 22.56.

What is the PB ratio of Alembic Pharmaceuticals Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM, the price-to-book (PB) ratio for Alembic Pharmaceuticals Ltd share is 285.67.

How to Buy Alembic Pharmaceuticals Ltd Share?

Answer Field

You can trade in Alembic Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Alembic Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Alembic Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Alembic Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|